Literature DB >> 22123366

Right ventricular dysfunction compromises accuracy of echocardiographic diagnosis of pulmonary hypertension in heart failure.

Angela McClanahan1, Maya Guglin.   

Abstract

BACKGROUND: The Swan-Ganz catheter and echocardiography (ECHO) are commonly used to measure pulmonary artery systolic pressure. It is unknown how right ventricular dysfunction influences the accuracy of ECHO-derived estimation of pulmonary hypertension in patients with severe left ventricular systolic dysfunction. METHODS AND
RESULTS: We analyzed a limited-access dataset from the ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness) trial provided by the National Heart, Lung, and Blood Institute. Patients enrolled in this trial had left ventricular ejection fraction <30% and decompensated heart failure (HF). Preserved and depressed right ventricular function was defined as fractional area change ≥30% and <30%, respectively. Pearson correlation coefficient, sensitivity, and specificity were calculated. In 106 patients, there were serial measurements of pulmonary artery systolic pressure with both Swan-Ganz catheter and ECHO. For all points of time, including admission for HF decompensation, next day (subcompensation), and the last day of hemodynamic measurements (compensation), correlation was better for preserved than for depressed right ventricular function.
CONCLUSIONS: Accuracy of echocardiographic estimation of pulmonary hypertension in patients with systolic HF is better when right ventricular systolic function is preserved.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22123366     DOI: 10.1016/j.cardfail.2011.08.011

Source DB:  PubMed          Journal:  J Card Fail        ISSN: 1071-9164            Impact factor:   5.712


  7 in total

Review 1.  Doppler trans-thoracic echocardiography for detection of pulmonary hypertension in adults.

Authors:  Yasushi Tsujimoto; Junji Kumasawa; Sayaka Shimizu; Yoshio Nakano; Yuki Kataoka; Hiraku Tsujimoto; Michihiko Kono; Shinji Okabayashi; Haruki Imura; Takahiro Mizuta
Journal:  Cochrane Database Syst Rev       Date:  2022-05-09

Review 2.  Left ventricular dysfunction with pulmonary hypertension: part 2: prognosis, noninvasive evaluation, treatment, and future research.

Authors:  Andreas P Kalogeropoulos; Vasiliki V Georgiopoulou; Barry A Borlaug; Mihai Gheorghiade; Javed Butler
Journal:  Circ Heart Fail       Date:  2013-05       Impact factor: 8.790

3.  Echocardiographic predictors of mortality in patients with pulmonary hypertension and cardiopulmonary comorbidities.

Authors:  Johannes Steiner; Wen-Chih Wu; Matthew Jankowich; Bradley A Maron; Satish Sharma; Gaurav Choudhary
Journal:  PLoS One       Date:  2015-03-16       Impact factor: 3.240

4.  Effects of Single Drug and Combined Short-term Administration of Sildenafil, Pimobendan, and Nicorandil on Right Ventricular Function in Rats With Monocrotaline-induced Pulmonary Hypertension.

Authors:  Telma M Nakata; Ryou Tanaka; Rieko Yoshiyuki; Toshiharu Fukayama; Seijiro Goya; Ryuji Fukushima
Journal:  J Cardiovasc Pharmacol       Date:  2015-06       Impact factor: 3.105

Review 5.  The Right Ventricle-You May Forget it, but It Will Not Forget You.

Authors:  Patrick M Wanner; Miodrag Filipovic
Journal:  J Clin Med       Date:  2020-02-05       Impact factor: 4.241

Review 6.  Pulmonary artery catheterization in acute myocardial infarction complicated by cardiogenic shock: A review of contemporary literature.

Authors:  Shiva P Ponamgi; Muhammad Haisum Maqsood; Pranathi R Sundaragiri; Michael G DelCore; Arun Kanmanthareddy; Wissam A Jaber; William J Nicholson; Saraschandra Vallabhajosyula
Journal:  World J Cardiol       Date:  2021-12-26

7.  Echocardiographic assessment of pulmonary artery systolic pressure and outcomes in ambulatory heart failure patients.

Authors:  Andreas P Kalogeropoulos; Sarawut Siwamogsatham; Salim Hayek; Song Li; Anjan Deka; Catherine N Marti; Vasiliki V Georgiopoulou; Javed Butler
Journal:  J Am Heart Assoc       Date:  2014-02-03       Impact factor: 5.501

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.